Group 1 - MIRXES-B has signed a memorandum of understanding with Apollo Health and Lifestyle Limited to seek strategic cooperation for the development and commercialization of advanced cancer early detection solutions in India and neighboring countries [1] - The anticipated joint venture in India will have a minimum equity value of $50 million, based on the intellectual property, clinical pipeline, research and clinical trial facilities, and commercial channels contributed by both companies [1] - Apollo is recognized as a leading healthcare provider in Asia and aims to enhance its global leadership position in preventive oncology and disease management [1] Group 2 - The collaboration will combine Mirxes' breakthrough miRNA and multi-omics technologies, core products (GASTROClear and LUNGClear), and its mature clinical pipeline with Apollo's extensive clinical expertise and nationwide hospital network [2] - The goal of the partnership is to scale the commercialization and market adoption of these solutions, thereby expanding the coverage of early disease screening in the region [2] - The board believes that this strategic cooperation with Apollo represents a significant synergistic opportunity that aligns with the long-term strategic goals of the company [2]
MIRXES-B与AHLL订立谅解备忘录以寻求进行战略合作